PubRank

A Nademanee

Author PubWeight™ 32.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998 2.76
2 Solid cancers after bone marrow transplantation. J Clin Oncol 2001 1.99
3 Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000 1.74
4 Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000 1.32
5 Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 2001 1.27
6 Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2009 1.18
7 Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994 1.06
8 Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000 1.06
9 A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003 1.03
10 Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001 0.98
11 Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995 0.96
12 Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant 1998 0.95
13 Monocytoid B-cell lymphoma. Clinicopathologic study of 21 cases of a unique type of low-grade lymphoma. Cancer 1988 0.93
14 Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. Biol Blood Marrow Transplant 2003 0.91
15 A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. Bone Marrow Transplant 2012 0.91
16 Immunoarchitecture of normal human bone marrow: a study of frozen and fixed tissue sections. Hum Pathol 1992 0.89
17 Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies. Leukemia 2012 0.88
18 Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore) 1996 0.88
19 Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant 2004 0.86
20 Sarcoidosis and lymphoma: an unusual association. Sarcoidosis 1987 0.85
21 Hepatitis C and B-cell lymphoma. Ann Intern Med 1998 0.85
22 High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 2000 0.84
23 Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 2006 0.83
24 Effects of allogeneic bone marrow transplantation on recipient bone mineral density: A prospective study. Biol Blood Marrow Transplant 2000 0.81
25 Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD. Bone Marrow Transplant 2009 0.79
26 Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 1999 0.79
27 In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 1996 0.77
28 Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1990 0.77
29 Bone marrow transplantation: the City of Hope experience. Clin Transpl 1995 0.76
30 Emergency double unrelated umbilical cord blood transplant for acute lymphoblastic leukemia after very late deferral of bone marrow donor. Bone Marrow Transplant 2007 0.76
31 Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation. Ann Oncol 2009 0.76
32 Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 2011 0.75
33 High-dose therapy and autologous bone marrow transplantation for Hodgkin's disease patients with relapses potentially treatable by radical radiation therapy. Int J Radiat Oncol Biol Phys 1995 0.75
34 Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. Radiother Oncol 1995 0.75
35 Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma. Cancer Treat Rep 1987 0.75
36 High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia 2000 0.75
37 Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995 0.75
38 Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center. Clin Transpl 2000 0.75